GUCS 2017: Early Immunotherapy Discontinuation in mRCC – Oncology Nurse Advisor
|
GUCS 2017: Early Immunotherapy Discontinuation in mRCC
Oncology Nurse Advisor Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early due to unacceptable toxicity may still achieve durable responses, according to a study that will be presented at the 2017 Genitourinary Cancers … |
